Skip to main content

Advertisement

SpringerLink
Log in

Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH–SETH

  • Review Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Venous thromboembolism (VTE) is a serious complication in hematologic neoplasms, so finding adequate prevention strategies is an urgent requirement. However, prospective studies with large enough cohorts are scarce, limiting the development of evidence-based thromboprophylaxis guidelines. The present position paper is addressed to all hematologists treating patients affected by hematologic neoplasms with the aim to provide clinicians with a useful tool for the prevention of VTE.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Availability of data and material

Not applicable for that section.

Code availability

Not applicable for that section.

Abbreviations

SETH:

Sociedad Española de Trombosis y Hemostasia

SEHH:

Sociedad Española de Hematología y Hemoterapia

References

  1. Falanga A, Russo L, Milesi V, Vignoli A. Mechanisms and risk factors of thrombosis in cancer. Crit Rev Oncol Hematol. 2017;118:79–83.

    Article  PubMed  Google Scholar 

  2. Colombo R, Gallipoli P, Castelli R. Thrombosis and hemostatic abnormalities in hematological malignancies. Clin Lymphoma Myeloma Leuk. 2014;14:441–50.

    Article  PubMed  Google Scholar 

  3. Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008;111:4902–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Ay C, Dunkler D, Marosi C, Chiriac A-L, Vormittag R, Simanek R, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010;116:5377–82.

    Article  CAS  PubMed  Google Scholar 

  5. Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R. A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med. 2012;7:291–2.

    Article  PubMed  Google Scholar 

  6. van Es N, Di Nisio M, Cesarman G, Kleinjan A, Otten H-M, Mahé I, et al. Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica. 2017;102:1494–501.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Gerotziafas GT, Taher A, Abdel-Razeq H, AboElnazar E, Spyropoulos AC, El Shemmari S, et al. A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS-cancer-associated thrombosis study. Oncologist. 2017;22:1222–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Cella CA, Di Minno G, Carlomagno C, Arcopinto M, Cerbone AM, Matano E, et al. Preventing venous thromboembolism in ambulatory cancer patients: the ONKOTEV study. Oncologist. 2017;22:601–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Muñoz Martín AJ, Ortega I, Font C, Pachón V, Castellón V, Martínez-Marín V, et al. Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. Br J Cancer. 2018;118:1056–61.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Di Nisio M, Porreca E, Candeloro M, De Tursi M, Russi I, Rutjes AW. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev [Internet]. 2016 [cited 2020 Jul 20];2016. Available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463937/

  11. Khorana AA, Francis CW, Kuderer NM, Carrier M, Ortel TL, Wun T, et al. Dalteparin thromboprophylaxis in cancer patients at high risk for venous thromboembolism: a randomized trial. Thromb Res. 2017;151:89–95.

    Article  CAS  PubMed  Google Scholar 

  12. Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med. 2019;380:720–8.

    Article  CAS  PubMed  Google Scholar 

  13. Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med. 2019;380:711–9.

    Article  CAS  PubMed  Google Scholar 

  14. Gheldof D, Haguet H, Dogné J-M, Bouvy C, Graux C, George F, et al. Procoagulant activity of extracellular vesicles as a potential biomarker for risk of thrombosis and DIC in patients with acute leukaemia. J Thromb Thrombolysis. 2017;43:224–32.

    Article  PubMed  Google Scholar 

  15. Del Principe MI, Del Principe D, Venditti A. Thrombosis in adult patients with acute leukemia. Curr Opin Oncol. 2017;29:448–54.

    Article  PubMed  Google Scholar 

  16. Orvain C, Balsat M, Tavernier E, Marolleau J-P, Pabst T, Chevallier P, et al. Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study. Blood. 2020;136:328–38.

    CAS  PubMed  Google Scholar 

  17. Grace RF, DeAngelo DJ, Stevenson KE, Neuberg D, Sallan SE, Mourad YRA, et al. The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia. J Thromb Thrombolysis. 2018;45:306–14.

    Article  CAS  PubMed  Google Scholar 

  18. Vu K, Luong NV, Hubbard J, Zalpour A, Faderl S, Thomas DA, et al. A retrospective study of venous thromboembolism in acute leukemia patients treated at the University of Texas MD Anderson Cancer Center. Cancer Med. 2015;4:27–35.

    Article  PubMed  Google Scholar 

  19. Mateos MK, Trahair TN, Mayoh C, Barbaro PM, Sutton R, Revesz T, et al. Risk factors for symptomatic venous thromboembolism during therapy for childhood acute lymphoblastic leukemia. Thromb Res. 2019;178:132–8.

    Article  CAS  PubMed  Google Scholar 

  20. Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Donati MB. Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukemia: results from a meta-analysis. J Thromb Haemost. 2007;5:621–3.

    Article  CAS  PubMed  Google Scholar 

  21. Caruso V, Iacoviello L, Di Castelnuovo A, Storti S, Mariani G, de Gaetano G, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood. 2006;108:2216–22.

    Article  CAS  PubMed  Google Scholar 

  22. Couturier M-A, Huguet F, Chevallier P, Suarez F, Thomas X, Escoffre-Barbe M, et al. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: the GRAALL experience. Am J Hematol. 2015;90:986–91.

    Article  CAS  PubMed  Google Scholar 

  23. Barreto JN, McCullough KB, Peskey CS, Dierkhising RA, Mara KC, Elliott MA, et al. Safety and feasibility of lower antithrombin replacement targets in adult patients with hematological malignancies receiving asparaginase therapy. Leuk Lymphoma. 2017;58:2588–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Zwicker JI, Wang T-F, DeAngelo DJ, Lauw MN, Connors JM, Falanga A, et al. The prevention and management of asparaginase-related venous thromboembolism in adults: guidance from the SSC on hemostasis and malignancy of the ISTH. J Thromb Haemost. 2020;18:278–84.

    Article  PubMed  Google Scholar 

  25. Rank CU, Toft N, Tuckuviene R, Grell K, Nielsen OJ, Frandsen TL, et al. Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years. Blood. 2018;131:2475–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Sibai H, Seki JT, Wang TQ, Sakurai N, Atenafu EG, Yee KWL, et al. Venous thromboembolism prevention during asparaginase-based therapy for acute lymphoblastic leukemia. Curr Oncol. 2016;23:e355–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Sibai H, Chen R, Liu X, Falcone U, Schimmer A, Schuh A, et al. Anticoagulation prophylaxis reduces venous thromboembolism rate in adult acute lymphoblastic leukaemia treated with asparaginase-based therapy. Br J Haematol. 2020.

  28. Wu Y-Y, Tang L, Wang M-H. Leukemia and risk of venous thromboembolism: a meta-analysis and systematic review of 144 studies comprising 162,126 patients. Sci Rep. 2017;7:1167.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Libourel EJ, Klerk CPW, van Norden Y, de Maat MPM, Kruip MJ, Sonneveld P, et al. Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia. Blood. 2016;128:1854–61.

    Article  CAS  PubMed  Google Scholar 

  30. Hambley B, Ciprian Tomuleasa C, Ghiaur G. Coagulopathy in acute promyelocytic leukemia: can we go beyond supportive care? Front Med (Lausanne). 2021;8:722614.

    Article  Google Scholar 

  31. Sanz MA, Montesinos P. Open issues on bleeding and thrombosis in acute promyelocytic leukemia. Thromb Res. 2010;125(Suppl 2):S51-54.

    Article  PubMed  Google Scholar 

  32. Kander EM, Zhao Q, Bhat SA, Hirsch J, Byrd JC, Ooka L, et al. Venous and arterial thrombosis in patients with haematological malignancy during treatment with ibrutinib. Br J Haematol. 2019;187:399–402.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogné J-M. Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival: a systematic review and meta-analysis. JAMA Oncol. 2016;2:625–32.

    Article  PubMed  Google Scholar 

  34. Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367:2075–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Cortes JE, Kim D-W, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369:1783–96.

    Article  CAS  PubMed  Google Scholar 

  36. Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17:612–21.

    Article  CAS  PubMed  Google Scholar 

  37. Dorer DJ, Knickerbocker RK, Baccarani M, Cortes JE, Hochhaus A, Talpaz M, et al. Impact of dose intensity of ponatinib on selected adverse events: multivariate analyses from a pooled population of clinical trial patients. Leuk Res. 2016;48:84–91.

    Article  CAS  PubMed  Google Scholar 

  38. Cortes JE, Kim D-W, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. 2018;132:393–404.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Loren CP, Aslan JE, Rigg RA, Nowak MS, Healy LD, Gruber A, et al. The BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear. Thromb Res. 2015;135:155–60.

    Article  CAS  PubMed  Google Scholar 

  40. Hamadi A, Grigg AP, Dobie G, Burbury KL, Schwarer AP, Kwa FA, et al. Ponatinib tyrosine kinase inhibitor induces a thromboinflammatory response. Thromb Haemost. 2019;119:1112–23.

    Article  PubMed  Google Scholar 

  41. Haguet H, Douxfils J, Chatelain C, Graux C, Mullier F, Dogné J-M. BCR-ABL tyrosine kinase inhibitors: which mechanism(s) may explain the risk of thrombosis? TH Open. 2018;2:e68-88.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Caruso V, Di Castelnuovo A, Meschengieser S, Lazzari MA, de Gaetano G, Storti S, et al. Thrombotic complications in adult patients with lymphoma: a meta-analysis of 29 independent cohorts including 18 018 patients and 1149 events. Blood. 2010;115:5322–8.

    Article  CAS  PubMed  Google Scholar 

  43. Sanfilippo KM, Wang TF, Gage BF, Luo S, Riedell P, Carson KR. Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma. Thromb Res. 2016;143:86–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Park LC, Woo S, Kim S, Jeon H, Ko YH, Kim SJ, et al. Incidence, risk factors and clinical features of venous thromboembolism in newly diagnosed lymphoma patients: results from a prospective cohort study with Asian population. Thromb Res. 2012;130:e6-12.

    Article  CAS  PubMed  Google Scholar 

  45. Santi RM, Ceccarelli M, Bernocco E, Monagheddu C, Evangelista A, Valeri F, et al. Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL). Thromb Haemost. 2017;117:1615–21.

    Article  Google Scholar 

  46. Rupa-Matysek J, Gil L, Kaźmierczak M, Barańska M, Komarnicki M. Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies: validation of the Khorana Risk Score. Med Oncol. 2017;35:5.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Lim SH, Woo S-Y, Kim S, Ko YH, Kim WS, Kim SJ. Cross-sectional study of patients with diffuse large B-cell lymphoma: assessing the effect of host status, tumor burden, and inflammatory activity on venous thromboembolism. Cancer Res Treat. 2016;48:312–21.

    Article  CAS  PubMed  Google Scholar 

  48. Antic D, Milic N, Nikolovski S, Todorovic M, Bila J, Djurdjevic P, et al. Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients. Am J Hematol. 2016;91:1014–9.

    Article  CAS  PubMed  Google Scholar 

  49. Borchmann S, Müller H, Hude I, Fuchs M, Borchmann P, Engert A. Thrombosis as a treatment complication in Hodgkin lymphoma patients: a comprehensive analysis of three prospective randomized German Hodgkin Study Group (GHSG) trials. Ann Oncol. 2019;30:1329–34.

    Article  CAS  PubMed  Google Scholar 

  50. Cronin-Fenton DP, Søndergaard F, Pedersen LA, Fryzek JP, Cetin K, Acquavella J, et al. Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997–2006. Br J Cancer. 2010;103:947–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Kristinsson SY, Pfeiffer RM, Björkholm M, Goldin LR, Schulman S, Blimark C, et al. Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study. Blood. 2010;115:4991–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Kristinsson SY, Tang M, Pfeiffer RM, Björkholm M, Blimark C, Mellqvist U-H, et al. Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. Blood. 2010;116:2651–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. De Stefano V, Za T, Rossi E. Venous thromboembolism in multiple myeloma. Semin Thromb Hemost. 2014;40:338–47.

    Article  PubMed  Google Scholar 

  54. Ocak G, Vossen CY, Verduijn M, Dekker FW, Rosendaal FR, Cannegieter SC, et al. Risk of venous thrombosis in patients with major illnesses: results from the MEGA study. J Thromb Haemost. 2013;11:116–23.

    Article  CAS  PubMed  Google Scholar 

  55. Anaissie EJ, Coleman EA, Goodwin JA, Kennedy RL, Lockhart KD, Stewart CB, et al. Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis. Cancer. 2012;118:549–57.

    Article  CAS  PubMed  Google Scholar 

  56. Al-Ani F, Bermejo JMB, Mateos M-V, Louzada M. Thromboprophylaxis in multiple myeloma patients treated with lenalidomide—a systematic review. Thromb Res. 2016;141:84–90.

    Article  CAS  PubMed  Google Scholar 

  57. Chakraborty R, Bin Riaz I, Malik SU, Marneni N, Mejia Garcia A, Anwer F, et al. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: a systematic review and meta-analysis. Cancer. 2020;126:1640–50.

    Article  CAS  PubMed  Google Scholar 

  58. Sanfilippo KM, Luo S, Wang T-F, Fiala M, Schoen M, Wildes TM, et al. Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. Am J Hematol. 2019;94:1176–84.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Li A, Wu Q, Luo S, Warnick GS, Zakai NA, Libby EN, et al. Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma. J Natl Compr Cancer Netw. 2019;17:840–7.

    Article  CAS  Google Scholar 

  60. Fotiou D, Gavriatopoulou M, Terpos E. Multiple myeloma and thrombosis: prophylaxis and risk prediction tools. Cancers (Basel). 2020;12:191.

    Article  CAS  Google Scholar 

  61. Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. Blood. 2012;119:933–9.

    Article  CAS  PubMed  Google Scholar 

  62. Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. J Clin Oncol. 2011;29:986–93.

    Article  CAS  PubMed  Google Scholar 

  63. Goldhaber SZ. Venous thromboembolism: epidemiology and magnitude of the problem. Best Pract Res Clin Haematol. 2012;25:235–42.

    Article  PubMed  Google Scholar 

  64. Gisslinger H, Gotic M, Holowiecki J, Penka M, Thiele J, Kvasnicka H-M, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial. Blood. 2013;121:1720–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. De Stefano V, Qi X, Betti S, Rossi E. Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment. Thromb Haemost. 2016;115:240–9.

    Article  PubMed  Google Scholar 

  66. Dentali F, Ageno W, Rumi E, Casetti I, Poli D, Scoditti U, et al. Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases. Thromb Res. 2014;134:41–3.

    Article  CAS  PubMed  Google Scholar 

  67. Taniguchi Y, Tanaka H, Luis EJ, Sakai K, Kumode T, Sano K, et al. Elevated plasma levels of procoagulant microparticles are a novel risk factor for thrombosis in patients with myeloproliferative neoplasms. Int J Hematol. 2017;106:691–703.

    Article  PubMed  Google Scholar 

  68. Ferrer-Marín F, Cuenca-Zamora EJ, Guijarro-Carrillo PJ, Teruel-Montoya R. Emerging role of neutrophils in the thrombosis of chronic myeloproliferative neoplasms. Int J Mol Sci. 2021;22:1143.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Carobbio A, Thiele J, Passamonti F, Rumi E, Ruggeri M, Rodeghiero F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117:5857–9.

    Article  CAS  PubMed  Google Scholar 

  70. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29:761–70.

    Article  PubMed  PubMed Central  Google Scholar 

  71. Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120:5128–33.

    Article  CAS  PubMed  Google Scholar 

  72. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2017;92:94–108.

    Article  CAS  PubMed  Google Scholar 

  73. Haider M, Gangat N, Lasho T, Abou Hussein AK, Elala YC, Hanson C, et al. Validation of the revised International prognostic score of thrombosis for essential thrombocythemia (IPSET-thrombosis) in 585 Mayo clinic patients. Am J Hematol. 2016;91:390–4.

    Article  PubMed  Google Scholar 

  74. Chu DK, Hillis CM, Leong DP, Anand SS, Siegal DM. Benefits and risks of antithrombotic therapy in essential thrombocythemia: a systematic review. Ann Intern Med. 2017;167:170–80.

    Article  PubMed  Google Scholar 

  75. Alvarez-Larrán A, Cervantes F, Pereira A, Arellano-Rodrigo E, Pérez-Andreu V, Hernández-Boluda J-C, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood. 2010;116:1205–10.

    Article  PubMed  Google Scholar 

  76. Alvarez-Larrán A, Pereira A, Guglielmelli P, Hernández-Boluda JC, Arellano-Rodrigo E, Ferrer-Marín F, et al. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica. 2016;101:926–31.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Kroll MH, Michaelis LC, Verstovsek S. Mechanisms of thrombogenesis in polycythemia vera. Blood Rev. 2015;29:215–21.

    Article  CAS  PubMed  Google Scholar 

  78. Barbui T, Carobbio A, Rumi E, Finazzi G, Gisslinger H, Rodeghiero F, et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood. 2014;124:3021–3.

    Article  PubMed  Google Scholar 

  79. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114–24.

    Article  CAS  PubMed  Google Scholar 

  80. Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368:22–33.

    Article  CAS  PubMed  Google Scholar 

  81. McMahon B, Stein BL. Thrombotic and bleeding complications in classical myeloproliferative neoplasms. Semin Thromb Hemost. 2013;39:101–11.

    CAS  PubMed  Google Scholar 

  82. Kaifie A, Kirschner M, Wolf D, Maintz C, Hänel M, Gattermann N, et al. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol. 2016;9:18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood. 2010;115:778–82.

    Article  CAS  PubMed  Google Scholar 

  84. Saliba W, Mishchenko E, Cohen S, Rennert G, Preis M. Association between myelofibrosis and thromboembolism: a population-based retrospective cohort study. J Thromb Haemost. 2020;18:916–25.

    Article  CAS  PubMed  Google Scholar 

  85. Zahid MF, Murad MH, Litzow MR, Hogan WJ, Patnaik MS, Khorana A, et al. Venous thromboembolism following hematopoietic stem cell transplantation-a systematic review and meta-analysis. Ann Hematol. 2016;95:1457–64.

    Article  PubMed  Google Scholar 

  86. Labrador J, Lopez-Anglada L, Perez-Lopez E, Lozano FS, Lopez-Corral L, Sanchez-Guijo FM, et al. Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients. Haematologica. 2013;98:437–43.

    Article  PubMed  PubMed Central  Google Scholar 

  87. A decade of experience in peripherally inserted central catheter (PICC) related thrombosis in hematological malignancies of a single Spanish center [Internet]. ISTH Congr. Abstr. [cited 2020 Jul 29]. Available from: https://abstracts.isth.org/abstract/a-decade-of-experience-in-peripherally-inserted-central-catheter-picc-related-thrombosis-in-hematological-malignancies-of-a-single-spanish-center/

  88. Lv Y, Hou Y, Pan B, Ma Y, Li P, Yu L, et al. Risk associated with central catheters for malignant tumor patients: a systematic review and meta-analysis. Oncotarget. 2018;9:12376–88.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20:e566–81.

    Article  PubMed  Google Scholar 

  90. Mavrovounis G, Mermiri M, Chatzis DG, Pantazopoulos I. Peripherally inserted central catheter lines for intensive care unit and onco-hematologic patients: a systematic review and meta-analysis. Heart Lung J Crit Care. 2020;49:922–33.

    Article  Google Scholar 

  91. Rajasekhar A, Streiff MB. How I treat central venous access device-related upper extremity deep vein thrombosis. Blood. 2017;129:2727–36.

    Article  CAS  PubMed  Google Scholar 

  92. Chopra V, Kaatz S, Conlon A, Paje D, Grant PJ, Rogers M, et al. The Michigan Risk Score to predict peripherally inserted central catheter-associated thrombosis. J Thromb Haemostat. 2017;15:1951–62.

    Article  CAS  Google Scholar 

  93. Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update. J Clin Oncol. 2020;38:496–520.

    Article  PubMed  Google Scholar 

  94. Kahale LA, Tsolakian IG, Hakoum MB, Matar CF, Barba M, Yosuico VE, et al. Anticoagulation for people with cancer and central venous catheters. Cochrane Database Syst Rev. 2018;6:CD006468.

    PubMed  Google Scholar 

  95. Pegourie B, Karlin L, Benboubker L, Orsini-Piocelle F, Tiab M, Auger-Quittet S, et al. Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study. Am J Hematol. 2019;94:635–40.

    Article  CAS  PubMed  Google Scholar 

  96. Storrar NPF, Mathur A, Johnson PRE, Roddie PW. Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide- and lenalidomide-containing regimens. Br J Haematol. 2019;185:142–4.

    Article  PubMed  Google Scholar 

Download references

Funding

No funding was received for this study.

Author information

Authors and Affiliations

  1. Hematology Department, Hospital Universitario de Salamanca, Instituto Biosanitario de Salamanca (IBSAL), Paseo de San Vicente, s/n, 37007, Salamanca, Spain

    J. R. Gonzalez-Porras & V. Gonzalez-Calle

  2. Thrombosis and Hemostasis Unit, Hematology Department, Hospital de La Santa Creu I Sant Pau, Barcelona, Spain

    J. Mateo

  3. Hematology Department, Instituto de Investigación Sanitaria y Biomedica de Alicante (ISABIAL), Hospital General Universitario de Alicante, Alicante, Spain

    P. Marco

  4. Hematology Department, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain

    V. Garcia-Gutierrez

  5. Hematology Department, Hospital Clinic, Barcelona, Spain

    J. C. Reverter

  6. Hematology Department, Clínica Universidad de Navarra, IdISNA, CIBERCV, Pamplona, Spain

    R. Lecumberri

Authors
  1. J. R. Gonzalez-Porras
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Mateo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. V. Gonzalez-Calle
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. P. Marco
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. V. Garcia-Gutierrez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. C. Reverter
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R. Lecumberri
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

JRG-P Conceptualization, Methodology, Writing—original draft, review & editing. JM: Supervision, Writing—review & editing. VG-C: Supervision, Writing—review & editing. PM: Supervision, Writing—review & editing. VG-G: Supervision, Writing—review & editing. JCR: Supervision, Writing—review & editing. RL: Conceptualization, Methodology, Supervision, Writing—review & editing.

Corresponding author

Correspondence to J. R. Gonzalez-Porras.

Ethics declarations

Conflict of interest

The authors report no declarations of interest. Financial activities outside the submitted work: Jose Ramon Gonzalez-Porras has received fees for consulting services by Amgen, Novartis, SOBI, Grifols and CSL Behring and speaking honoraria from Novo Nordisk, Shire, SOBI, Roche, Daiichi Sankyo, Pfizer, Rovi, Amgen, and Novartis. Jose Mateo has received speaking honoraria from Leo Pharma and Rovi. Veronica Gonzalez Calle has received research grant from Janssen (Beca SEHH-JANSSEN estancias de formación en el extranjero 2016–2017) and has been a consult for Prothena and Janssen. Pascual Marco has nothing to disclose. Valentin García-Gutierrez has received fees for consulting services by Novartis, BMS, Pfizer and Incyte, has received speaking nonoraria from Novartis, BMS and Pfizer and has received a research funding from Incyte, Celgene, Pfizer, Astellas. Joan Carles Reverter has nothing to disclose. Ramon Lecumberri has received a research grant from Rovi, has received fees for consulting services by Leo Pharma and has received speaking honoraria from Rovi, Leo Pharma, BMS, Sanofi & Daiichi-Sankyo.

Ethics approval

Not applicable for that section.

Consent to participate

Not applicable for that section.

Consent for publication

Not applicable for that section.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 48 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gonzalez-Porras, J.R., Mateo, J., Gonzalez-Calle, V. et al. Prevention of venous thromboembolism in hematologic neoplasms: an expert consensus from SEHH–SETH. Clin Transl Oncol 24, 770–783 (2022). https://doi.org/10.1007/s12094-021-02735-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-021-02735-1

Keywords

Search

Navigation